Company Overview
About Mammoth Biosciences
Mammoth Biosciences is a biotechnology company founded in 2017 by CRISPR pioneer and Nobel laureate Jennifer Doudna alongside Trevor Martin, Janice Chen, and Lucas Harrington. Headquartered in Brisbane, California, Mammoth focuses on developing ultracompact CRISPR systems that can be delivered in vivo using a single adeno-associated viral (AAV) vector — overcoming a major limitation of Cas9-based gene editors that are too large for efficient AAV delivery.
Business Model & Competitive Advantage
Mammoth''s flagship innovation is NanoCas, unveiled in January 2025 and described as the first efficient ultracompact extrahepatic gene editor. NanoCas efficiently edits skeletal muscle tissue in mice and non-human primates when delivered systemically — a breakthrough for treating muscular diseases and other extrahepatic conditions. The company also developed CasPhi, another ultracompact CRISPR nuclease significantly smaller than Cas9. Its lead clinical candidate, MB-111, is a potential first-in-class single-dose in vivo therapy for persistent chylomicronemia using CasPhi.
Competitive Landscape 2025–2026
In 2025, Mammoth presented preclinical data at ASGCT and the European Society of Gene & Cell Therapy congress, and announced a collaboration with Regeneron to pursue next-generation CRISPR-based gene editing across multiple diseases. Mammoth''s platform positions it as foundational infrastructure for the next wave of in vivo gene therapies targeting muscles, brain, and other organs where existing gene editing tools cannot reach.
Key Differentiators
Strong Challenger
Mammoth Biosciences is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Compare Mammoth Biosciences with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Mammoth Biosciences? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Mammoth Biosciences Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Mammoth Biosciences vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →